On Feb. 20, biomedical-technology specialist Nanogen
- Revenues showed a huge growth of 184% as a result of acquired revenue and organic growth.
- The company issued an additional $7.5 million of stock to enhance its cash resources in the quarter.
- Nanogen expects year-over-year annual revenue growth to exceed 50% in 2007.
- The company is a two-star stock in Motley Fool CAPS, the Fool's community-based stock-rating service.
(Figures in thousands, except per-share data)
Income Statement Highlights
|
Q4 2006 |
Q4 2005 |
Change |
|
|---|---|---|---|
|
Sales |
$8,684 |
$3,062 |
183.6% |
|
Net Profit |
($11,238) |
($69,678) |
N/A |
|
EPS |
($0.17) |
($1.27) |
N/A |
|
Diluted Shares |
67,968 |
54,689 |
24.3% |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q4 2006 |
Q4 2005 |
Change* |
|
|---|---|---|---|
|
Gross Margin |
59.2% |
52.8% |
6.4 |
|
Operating Margin |
(126.3%) |
(2,288.6%) |
2,162.4 |
|
Net Margin |
(129.4%) |
(2,275.6%) |
2,146.2 |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$25,184 |
$32,379 |
(22.2%) |
|
Accounts Rec. |
$11,568 |
$2,141 |
440.3% |
|
Inventory |
$7,691 |
$3,724 |
106.5% |
|
Liabilities |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Accounts Payable |
$13,396 |
$7,728 |
73.3% |
|
Long-Term Debt |
$25,774 |
$9,682 |
(166.2%) |
Learn the ways of the balance sheet.
Cash Flow Highlights
No data available.
Find out why Fools always follow the money.
Related Companies:
-
Applera
(NYSE:ABI) -
Biosite
(NASDAQ:BSTE) -
Transgenomic
(NASDAQ:TBIO) -
Affymetrix
(NASDAQ:AFFX) -
CuraGen
(NASDAQ:CGEN)
Related Foolishness:
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
